Zymeworks Inc.(ZYME)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,925 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ZYME
Events flagged as statistical outliers against ZYME's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-06
ZYME quality score dropped 20 points (27→8) on a new filing
View source filing →
ZYME Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Zymeworks Inc. (ZYME), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZYME at 8.7/100 on a 32-signal composite quality model, placing it at rank #2,925 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (3.5) and profitability (3.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Zymeworks Inc. reports quarterly revenue of $4.6M, net income of $-45.0M, free cash flow of $-31.9M. Top institutional holders of ZYME by reported 13-F value include EcoR1 Capital, Rubric Capital Management, BlackRock, based on the most recent SEC filings. ZYME trades on the Nasdaq exchange and files with the SEC under CIK 1937653. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZYME daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zymeworks Inc. directly from SEC EDGAR. Zymeworks Inc.'s 13F Pro composite quality score has ranged between 8 and 33 since 2023, currently 8.7 — a declining long-term trajectory across 60 quarterly and live scoring snapshots.
Revenue
Q2 2026
$4.6M
Net Income
Q2 2026
$-45.0M
Free Cash Flow
Q2 2026
$-31.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+38.9% YoYNet Income
+33.9% YoYOperating Income
+32.5% YoYEPS (Diluted)
+33.3% YoYTotal Assets
-25.2% YoYOp. Cash Flow
+70.0% YoYFree Cash Flow
+69.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $106.0M +38.9% | $76.3M +0.4% | $76.0M -81.6% | $412.5M +1446.0% | $26.7M -31.5% | $39.0M |
| Net Income | $-81.1M +33.9% | $-122.7M -3.4% | $-118.7M -195.4% | $124.3M +158.7% | $-211.8M -17.3% | $-180.6M |
| Operating Income | $-92.5M +32.5% | $-137.1M +0.7% | $-138.1M -205.8% | $130.5M +160.5% | $-215.6M -15.0% | $-187.5M |
| EPS (Diluted) | $-1.08 +33.3% | $-1.62 +5.8% | $-1.72 -190.5% | $1.90 +141.2% | $-4.61 -28.8% | $-3.58 |
| Total Assets | $346.5M -25.2% | $463.1M -20.3% | $580.9M -10.5% | $648.7M +66.7% | $389.1M | — |
| Operating Cash Flow | $-33.0M +70.0% | $-110.1M +7.0% | $-118.3M -182.1% | $144.1M +174.9% | $-192.5M -27.1% | $-151.4M |
| Free Cash Flow | $-34.5M +69.2% | $-112.0M +7.2% | $-120.8M -188.8% | $136.0M +166.4% | $-204.9M -31.6% | $-155.7M |
Get alerted when ZYME's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Zymeworks Inc. including:
Top Institutional Holders of ZYME
EcoR1 Capital, LLC
$600.4M22,970,388 shRubric Capital Management LP
$183.0M7,000,000 shBlackRock, Inc.
$111.1M4,251,030 shPERCEPTIVE ADVISORS LLC
$109.3M4,182,953 shBVF INC/IL
$95.4M3,649,142 shMORGAN STANLEY
$58.3M2,231,260 shBNP Paribas Asset Management Holding S.A.
$46.6M1,781,116 shVANGUARD CAPITAL MANAGEMENT LLC
$40.8M1,558,998 shAssenagon Asset Management S.A.
$32.7M1,252,027 shNextech Invest, Ltd.
$29.1M1,113,946 sh
| Fund | Value | Shares |
|---|---|---|
| EcoR1 Capital, LLC | $600.4M | 22,970,388 |
| Rubric Capital Management LP | $183.0M | 7,000,000 |
| BlackRock, Inc. | $111.1M | 4,251,030 |
| PERCEPTIVE ADVISORS LLC | $109.3M | 4,182,953 |
| BVF INC/IL | $95.4M | 3,649,142 |
| MORGAN STANLEY | $58.3M | 2,231,260 |
| BNP Paribas Asset Management Holding S.A. | $46.6M | 1,781,116 |
| VANGUARD CAPITAL MANAGEMENT LLC | $40.8M | 1,558,998 |
| Assenagon Asset Management S.A. | $32.7M | 1,252,027 |
| Nextech Invest, Ltd. | $29.1M | 1,113,946 |
Companies Similar to ZYME
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Nurix Therapeutics, Inc.
Stoke Therapeutics, Inc.
Silence Therapeutics plc
Monte Rosa Therapeutics, Inc.
CytomX Therapeutics, Inc.
Atara Biotherapeutics, Inc.
Arcus Biosciences, Inc.
ALUMIS INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ZYME on your watchlist
Track score changes the day Zymeworks Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ZYME a good stock to buy?
13F Pro's AI-powered analysis of Zymeworks Inc. (ZYME) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZYME are available on the ZYME stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ZYME is classified as a small company.
Which hedge funds own ZYME?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZYME. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Zymeworks Inc.'s investment landscape.